Oligometastatic Prostate Carcinoma Clinical Trial
Official title:
OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate
The proposed study consists of a multicentre prospective observational study involving patients with oligometastatic prostatic neoplasia defined according to CHAARTED criteria. The aim of the study is the creation of a registry including patients with newly diagnosed OMPCa, belonging to the main urological centres in the Triveneto region, in order to evaluate the oncological outcomes and the impact on the quality of life of local treatment of the primary neoplasm (surgical or radiotherapy) in addition to systemic hormonal treatment (ADT as monotherapy or in combination with Docetaxel/androgen receptor signal inhibitors (ARTA)). The above criteria define 'high metastatic volume' disease with the following parameters - ≥ 4 bone metastases, including at least one outside the spine and pelvis - Presence of visceral metastases Consequently, patients included in the study should not have the above-mentioned characteristics.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05496959 -
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
|
Phase 2 | |
| Withdrawn |
NCT04585932 -
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
|
Phase 2 | |
| Not yet recruiting |
NCT05707468 -
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
|
N/A | |
| Recruiting |
NCT06389786 -
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
|
N/A | |
| Active, not recruiting |
NCT04190446 -
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment
|
Phase 2 | |
| Recruiting |
NCT06205316 -
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
|
Phase 3 | |
| Recruiting |
NCT05053152 -
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06369610 -
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
|
Phase 2 |